ArticleFrontiers in oncology2026
Radiomics-based MRI model for differentiating ovarian cystadenoma and cystadenocarcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate differentiation between benign and malignant ovarian tumors is crucial to ensure timely intervention for high-risk patients and minimizing overtreatment in others. Thus, the objective was to develop a radiomics-based machine learning model to differentiate between non-cancerous and cancerous lesions in ovaries. Methods: This retrospective study included 271 patients with ovarian cystadenocarcinoma and 266 patients with ovarian cystadenoma who underwent T2-weighted magnetic resonance imaging (MRI). Lesions were manually segmented, and 2286 radiomics features were extracted. Following dimensionality reduction, features were used to train machine learning models with different combinations of data scaling (min-max, Z-score, and quantile transformations) and classifiers (logistic regression and partial least squares discriminant analysis). In addition, a model combining radiomics features and cancer biomarker data (CA-125 and HE-4) was developed. Models were compared using the DeLong's test and McNemar's tests. Results: A total of 37 features were used for model development. The quantile logistic regression model exhibited the highest performance, achieving an AUC of 0.92, a sensitivity of 0.87, and a specificity of 0.83, which was significantly higher compared to all models except for Z-score logistic regression model. The inclusion of serum biomarkers (CA-125 and HE-4) significantly improved the performance of the model. Conclusion: T2-weighted MRI radiomics-based models accurately differentiated between benign and malignant epithelial ovarian tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.